Table 2 Treatments and clinical responses of advanced CRC patients included in the pilot trial
Subject ID | First cure Results of first evaluation | Second cure Results of second evaluation | Third cure Results of third evaluation | Survival time (months) at end of study |
|---|---|---|---|---|
01a | 5-FU + Radiotherapy Disease progression | 8 C FOLFIRI Disease progression | 1 C 5-FU Disease progression | 27 |
02 | 4 C FOLFOX Stable disease | 4 C FOLFOX Stable disease | 4 C FOLFOX Complete response | 31 |
03a | 1 C 5-FU Disease progression | 4 C Panitumumab Disease progression | – Disease progression | 08 |
04a | 4 C FOLFOX + Bevacizumab Partial response | 4 C FOLFOX + Bevacizumab Stable disease | 4 C Bevacizumab Disease progression | 21 |
05b | 6 C FOLFOX + Bevacizumab Stable disease | 4 C FOLFOX + Bevacizumab Disease progression | Bevacizumab Disease progression | 25 |
06b | 4 C FOLFIRI + Bevacizumab Stable disease | 4 C FOLFIRI + Bevacizumab Stable disease | 4 C Bevacizumab Disease progression | 24 |
07 | 3 C 5-FU Stable disease | 4 C 5-FU Stable disease | 1 C 5-FU Complete response | 24 |
08 | 3 C FOLFOX Stable disease | 4 C FOLFOX Disease progression | 4 FOLFIRI Disease progression | 31 |
09a,b | 4 C FOLFOX Disease progression | 4 C FOLFIRI + Bevacizumab Stable disease | 4 C FOLFIRI Stable disease | 14 |
10 | 8 C FOLFOX Stable disease | 4 C FOLFOX Stable disease | N/A Stable disease | 17 |
11 | 3 C 5-FU Stable disease | N/A Stable disease | N/A Stable disease | 16 |
12 | 4 C FOLFIRI + Bevacizumab Stable disease | 4 C FOLFIRI + Bevacizumab Partial response | 4 C Bevacizumab Stable disease | 15 |
13 | 3 C 5-FU Stable disease | 2 C 5-FU Stable disease | 2 C 5-FU Stable disease | 15 |
14 | 8 C FOLFOX Stable disease | 4 C 5-FU + Folinic acid Stable disease | N/A Stable disease | 15 |
15 | 4 C FOLFOX + Bevacizumab Partial response | 9 C FOLFOX + Bevacizumab Stable disease | N/A Partial response | 14 |
16 | 6 C FOLFOX Stable disease | 4 C FOLFOX Stable disease | 4 C FOLFOX Stable disease | 14 |
17 | 7 C FOLFOX + Bevacizumab Disease progression | 5 C FOLFOX + Bevacizumab Stable disease | N/A Stable disease | 14 |
18 | 4 C FOLFOX Partial response | 5 C FOLFOX + Bevacizumab Partial response | N/A Partial response | 14 |
19 | 3 C 5-FU Stable disease | 3 C 5-FU Stable disease | 3 C 5-FU Disease progression | 13 |